FF 
Prtncipai InveattgalooPTograni CXrodor (IjLSt, fIrsC. mkIcSo) 
2. Chong ASF, Hersh EM, Grimes WJ, Blocking of lymphokine acrivared killer (LAK) cell mediated 
cytotoxicity by ceU sized beads bearing tumor cell proteins. J Immunol 141(12);4418-4424, 1988. 
3. Chong ASF, Scuderi P, Grimes WJ, Hersh EM. Tumor targets stimulate IL-2 activated killer cells to 
produce Interferon-g and tumor necrosis factor^. J Immunol 142:2133-2139, 1989. 
4. Hersh EM, Scudeii P, Grimes WJ, Chong A, Brailey JL, Gschwind CR, Salmon SE. Cytostatic and 
cytotoxic activity of lymphokine activated killer (LAK) ceU supernatants. Cancer Immunol 
Immunother 30(l):65-70, 1989. 
5. Hersh EM, Murray JL, Hong WK, Rosenblum MG, Rueben JM, Wellbaecher R, Sarwal AN, Bradley 
EC,. Amett FC. Phase I study of cancer therapy with recombinant inrerleukin-2 administered by 
intravenous bolus injection. Biotherapy 1:215-226, 1989. 
6. Schwartz JE, Scuderi P, Wiggins C, Rudolph A, Hersh EM. A phase I trial of recombinant tumor 
necrosis factor (rTNF) administered by continuous intravenous mfmd on in patients with disseminated 
malignancy. Biotherapy 1:207-214, 1989. 
7. Her^ EM, Funk CTY’, Petersen EA, Mosier DE and the Ditiocarb Study Group. Biological activity of 
diethyldithlocarbamate (Ditiocarb, Imuthiol^) in an anim al model of retrovirus-induced 
immnnnd /»firif»rury anri in gliniral trials in parif»nfs with HIV infpf-rinn TVvf»lnp Rinl .Standard 
72:355-353, 1990 
8. Hersh EM, Brewton G, Abrams D, Bartlett J, Galpin J, Gill P, Goiter R. Gottileb M, Jonikas J, 
Landesman S, Levine A, Marcel A, Petersen EA, Whiteside M, Zahradnik J, Negron C, Boutitle F, 
Caraux J, Dupuy JM, Salmi LR, Ditiocarb sodium (diethyldithlocarbamate) therapy m patients with 
symptomatic HTV infection and AIDS. A randomized double-blind placebo-controlled multicenter 
smdy. JAMA 265:1538-1544, 1991. 
9. Hersh EM, Funk, CY, Ryschon KL, Petersen EA, Mosier DE. Effective therapy of the LP-BM5 
murine retrovirus-induced lymphoproliferative immunodeficiency disease with 
diethyldithlocarbamate, AIDS Research and Human Retroviruses 7:553-561, 1991. 
10. Hersh EM, Metch BS, Muggia FM, Brown TD, Whitehead RP, Budd GT, Rinehart JJ, Crawford ED, 
Bonnet JD, Behrens BC. Phase II studies of recombinant human tumor necrosis factor alpha 
(rhuTNFa) in patients with malignant disease. J Imm unotherapy 10:426^31,1991 
1 1. Lake D, Kawamura T, Tomiyama T, Masuho Y, Matsumoto Y, Robinson, Jr. WE, HERSH I 
ElM:Generation and Characterization of a human monoclonal antibody that neutralizes diverse HIV- i 
1 isolates in vitro. Current Science, AIDS, 6:1724, 1992. f 
12. Taylor CW, Chase EM, Whitehead RP, Rinehart JJ, Neidhart Ji^ Gonzalez R, Bunn PA, j^RSH | 
EM: A southwest oncology group phase I study of the sequential combination of recombinant | 
interferon-y and recombinant interieukin-2 in patients with cancer. J Immunotherapy, 11:176-183, * 
1992. I 
13. Verdi CJ, Taylor CW, Grogan MK, Dalke P, Meyskens FL, HERSH EM: Phase I study of low-dose 
cyclosphosphamide and recombinant LQterieukin-2 for the treatment of advanced cancer. J 
Immunotherapy, 11:286-291, 1992. 
14. Funk CY, Eisman J, Hersh JEM: Treatment of the murine, retrovirus-induced lyrnphoproliferative 
immunodeficiency disease (LP-BM5) in C57BL/10 mice with the knmunomodulator imexon. AIDS 
Research and Human ReUroviruses, 8:633-638, 1992 
15. HERSH EM, Gschwind C, Taylor CW, Dorr RT, Taetle R and Salmon SE: Anti proliferative and 
anti-tumor activity of the cyanoaziridinc compound imexon on tumor cell lines and fresh tumor cells 
in-vitro. JNCL 84:1238-1244, 1992. 
16. HERSH EM, Grogan TM, Funk CY and Taylor CW : Suppression of human lymphoma 
development in the SCID mouse by imexon therapy. J Iii^unotherapy, 13:77-83, 1993. 
17. HERSH ElMJ^unk CY, Petersen EA, Ryschon KL and Mosier, DE: Dose response and tim i n g 
effects in the therapy of the LP-BM5 murine retrovirus induced lymphoproliferative j 
immunodeficiency disease with diethyldiihiocarbamatc. Int J Iimnunopharmac, 15:137-143, i |’ 
1993.. _ I 
18. Barbuto JAM, Verasiegui EL and HERSH EM: The use of transformed T cell lines for clonal 
expansion of human B cells from peripheral blood, spleen and tumor infiltraring lymphocytes. “ 
Hybridoma, 12:115-125, 1993. ; 
19. Punt CJA, Barbuto JAM, Grimes WJ, and HERSH EM: Anti-tumor antibody production by 
tumor- infiltrating ( llBL) and peripheral blood (PBBL) human B lymphocytes. Cancer Research , 
(Submitted). 
20. Dorr RT, Liddil JD, Dalton WS, Caller L, and HERSH ElM: The 2 cyanoaziridine derivative 
imexon induces protein-associated DNA-singie strand breaks in human 8226 myeloma cells. 
Cancer Research. (Submitted). 
[260] Recombinant DNA Research, Volume 19 
